Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery (BARI)

NCT03294850 is registered in ClinicalTrials.gov with AdventHealth Translational Research Institute as lead sponsor.

NCT NCT03294850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03294850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery (BARI)
Lead sponsor
AdventHealth Translational Research Institute
Phase
Not applicable
Overall status
Completed
Start date
July 18, 2018
Completion date
September 11, 2020
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis; nafld - nonalcoholic fatty liver disease